Orphan Drugs Service Market Report 2026

The orphan drugs service market size has grown rapidly in recent years. It will grow from $43.4 billion in 2025 to $50.75 billion in 2026 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to growth in rare disease identification, expansion of orphan drug legislation, increasing investment in rare disease research, availability of regulatory incentives, rising role of patient advocacy groups.

The orphan drugs service market size is expected to see rapid growth in the next few years. It will grow to $93.93 billion in 2030 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to increasing demand for personalized rare disease therapies, rising adoption of advanced clinical trial technologies, expansion of global orphan drug pipelines, growing use of real-world evidence, continued regulatory support for orphan drug development. Major trends in the forecast period include increasing demand for specialized regulatory and development services, growing focus on accelerated approval pathways, rising use of data-driven rare disease research platforms, expansion of patient-centric clinical development models, enhanced collaboration between stakeholders.

The increasing investment in rare diseases is expected to drive the growth of the orphan drugs service market in the coming years. A rare disease is a medical condition that affects a small portion of the population, generally fewer than 1 in 2,000 individuals. These conditions are often chronic, progressive, and can be life-threatening or disabling. Investment in rare diseases is largely driven by the rising recognition of unmet medical needs and the potential for significant returns through regulatory incentives such as orphan drug designation, market exclusivity, and lower development costs. Rising investment in rare diseases strengthens orphan drug services by providing greater funding for research and development, enabling the creation of therapies for previously overlooked conditions. It speeds up drug availability by supporting clinical trials, regulatory approvals, and patient access, thereby improving treatment options for individuals with rare diseases. For example, in April 2024, according to Global Genes, a US-based nonprofit organization, companies working on drugs for rare diseases raised $7.1 billion in the first quarter of 2024, representing a 307% increase compared to the $1.8 billion raised in the same period in 2023. Consequently, the increasing investment in rare diseases is fueling the growth of the orphan drugs service market.

Major companies operating in the orphan drugs service market are prioritizing obtaining regulatory approvals to accelerate the development and accessibility of treatments for rare diseases. Regulatory approvals are official authorizations from government agencies that permit a drug or therapy to be legally tested, manufactured, and marketed for patient use. For example, in February 2023, Askbio GmbH, a US-based gene therapy company, was granted the European Commission orphan drug designation for AB-1003, a novel investigational gene therapy for limb-girdle muscular dystrophy. This adeno-associated virus (AAV)-based therapy is designed to restore FKRP enzyme activity in muscle cells through a single intravenous infusion. AB-1003 has received orphan drug designation from both the European Commission and the U.S. Food and Drug Administration (FDA), as well as rare pediatric disease and fast track designations from the FDA, emphasizing the urgent unmet medical need. It is currently being evaluated in a Phase 1/2 clinical trial (LION-CS101) to assess safety and efficacy in adults with genetically confirmed limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

In April 2025, Norgine B.V., a pharmaceutical company based in the Netherlands, acquired Theravia Pharma for an undisclosed sum. Through this acquisition, Norgine aims to strengthen its growth trajectory and rare disease portfolio by broadening its range of transformative therapies for patients with significant unmet medical needs in Europe and ANZ, positioning Norgine as a key partner in rare and specialty pharmaceuticals. Theravia Pharma is a pharmaceutical company based in France that specializes in rare diseases and orphan drug services.

Major companies operating in the orphan drugs service market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca PLC, The Bristol-Myers Squibb Company, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., IQVIA Inc., CSL Behring GmbH, Lonza Group AG, BioMarin Pharmaceutical Inc., Fortrea Holdings Inc., Medpace Inc., Sarepta Therapeutics, Caidya Inc., Cevidra Inc.

North America was the largest region in the orphan drugs service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orphan drugs service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the orphan drugs service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the orphan drugs service market by increasing costs of imported laboratory reagents, clinical trial equipment, data management systems, and specialized pharmaceutical inputs required for rare disease drug development. Service providers in North America and Europe are most affected due to reliance on globally sourced research tools, while Asia-Pacific faces higher costs for export-oriented development services. These tariffs are increasing service delivery costs and extending development timelines. However, they are also encouraging regional service localization, domestic research infrastructure investment, and stronger local regulatory support ecosystems.

The orphan drugs service market research report is one of a series of new reports that provides orphan drugs service market statistics, including orphan drugs service industry global market size, regional shares, competitors with a orphan drugs service market share, detailed orphan drugs service market segments, market trends and opportunities, and any further data you may need to thrive in the orphan drugs service industry. This orphan drugs service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Orphan drugs service is a specialized area of healthcare and pharmaceutical support that concentrates on supporting the research, development, approval, and accessibility of medications designed to treat rare diseases, which impact only a small and often underserved segment of the population. This service is vital in ensuring that these crucial medications can successfully navigate the complex regulatory and development procedures, ultimately providing access to patients who have few or no alternative treatment options.

The primary categories of orphan drug services include congenital disease, genetic disease, tumors and cancer, chronic conditions, and others. Congenital diseases are medical conditions present from birth, resulting from genetic abnormalities, developmental issues during pregnancy, or environmental factors affecting fetal development. These drugs are utilized across various therapeutic areas, such as oncology, metabolic disorders, neurological disorders, hematology, infectious diseases, and more, and are applicable for both adults and children.

The orphan drugs service market includes revenues earned by entities through clinical trial management, pharmacovigilance and safety monitoring, distribution and supply chain services, patient support and access programs, and data management and biostatistics services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.